Data from the KEYNOTE-B61 trial show tumor shrinkage in different types of kidney cancer, including papillary and chromophobe ...

There is currently no effective therapy for patients with advanced HLRCC-associated papillary renal cell carcinoma. Treatment with bevacizumab and erlotinib resulted in a confirmed response of 72% ...

Adding casdatifan to Cabometyx therapy showed encouraging activity and was generally well tolerated in previously treated ...

Jackson-Spence F, Larkin J, Patel P, et al. Final overall survival and new ctDNA analysis in MET-driven advanced papillary renal cancer (CALYPSO). Presented at ASCO GU 2025. February 13-15, 2025.

Racial disparities in renal cell carcinoma histology and outcomes: Insights from the French Kidney Cancer Research Network (UroCCR-191). Final overall survival and new ctDNA analysis in MET-driven ...

Twenty-five studies evaluating N4 positivity in GU tumors were included, 14 on UBC, three on upper tract urothelial carcinoma (UTUC), six on histologic subtypes (HS) and divergent histology of the ...